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The aim of the study: To analyze hu-
man breast cancer cell line MCF-7 and 
human malignant melanoma cell line 
WM-115 in order to characterize the 
cellular expression of CP and to evalu-
ate whether ATO may affect this activ-
ity, as well as the viability of the cells. 
Material and methods: The inhibitory 
effect of arsenic trioxide on the pro-
liferation of MCF-7 and WM-115 cells 
were measured with MTT test. The ac-
tivity of cancer procoagulant after ATO 
exposure was determined by a specif-
ic three-stage chromogenic assay. 
Results: ATO decreased the CP activity 
in a dose- and time-dependent man-
ner in MCF-7 cells with no effect on 
cell proliferation at the same time. 
However, it affected the CP activity of 
WM-115 cells in a  different way. Re-
duction in CP activity was followed by 
an increase after 48 h incubation. The 
cells viability results showed dose- 
and time-correlated response within 
high arsenic concentrations.
Conclusions: Arsenic trioxide down-
regulates the CP expression in human 
breast cancer and melanoma cells.
Key words: arsenic trioxide, cancer pro-
coagulant, breast cancer, melanoma.
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Introduction
Blood coagulation plays an important role in the occurrence of cancer. Ac-
tivation of the coagulation system in malignancy enables tumor spreading 
and thus it is associated with poor prognosis [1–3]. Tumor cells are able to 
initiate blood clotting cascade due to expression of various procoagulants 
and inflammatory cytokines, and the interaction between tumor cells and 
blood (i.e. monocytes/macrophages, platelets) and endothelial cells [4]. Two 
major procoagulants from malignant tissues are tissue factor (TF) and can-
cer procoagulant (CP) [2].
Tissue factor (TF) is a transmembrane glycoprotein expressed by normal 
and malignant tissues [3]. Cancer procoagulant belongs to cysteine protein-
ase superfamily and is described in malignant and fetal, but not in normally 
differentiated tissues [1, 3, 5]. The mechanisms of interactions between ma-
lignant cell and CP are still not well established. It is accepted that CP has 
proadhesive properties together with factor X-activating activity [6]. Exper-
imental data suggest that CP plays an important role in tumor growth and 
metastasis [1]. 
Arsenic trioxide has been confirmed to be an effective cure for relapsed 
acute promyelocytic leukemia (APL) patients [7]. Acute promyelocytic leuke-
mia is characterized by a special clinical picture with severe bleeding diathe-
sis. The coagulopathy of patients with APL has been a challenge for clinical 
hematology, especially during cytotoxic chemotherapy. Excessive procoagu-
lant activity in APL is related to generation of factor Xa via expressed TF as 
well as CP [8, 9]. Since 1988 all-trans retinoic acid (ATRA) has been introduced 
for treatment of APL with beneficial effects [10–12]. Recently, arsenic trioxide 
has also been used clinically as an effective therapeutic agent in relapsed 
ATRA-resistant patients. It is worth emphasizing that both ATRA and ATO in-
duced remission of the bleeding symptoms [13]. The effectiveness of arsenic 
in the therapy of leukemia was the basis for further studies and its applica-
tion in treatment of solid tumors. It has been evidenced that ATO induces 
apoptosis via alteration of cell cycle phases, activating apoptotic caspases in 
MCF-7 cell model [14]. However, there is no studies describing the impact of 
ATO on cellular procoagulant activity in solid tumor cell.
Breast cancer is associated with an increased risk of thrombosis particu-
larly during chemotherapy and hormone-therapy [15]. Chemotherapy could 
be accompanied by venous thromboembolism, observed in about 18% of 
advanced breast cancer patients [16, 17]. We chose breast cancer cell line, 
because several studies reported significant changes in coagulation markers 
in response to chemotherapy [16].
Melanoma-associated DIC (disseminated intravascular coagulation) has 
rarely been reported. However, there have been reports concerning other co-
agulation disorders associated with melanoma such as micro-angiopathic 
haemolytic anemia and subacute primitive fibrinolysis [18, 19]. A study of 
coagulation and fibrinolysis parameters of patients suffering from malig-
nant melanoma compared with controls evidenced increased rates of coag-
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ulation parameters [18]. TF could play an important role in 
evolution of DIC in melanoma. However, human malignant 
melanoma cell line WM-115 is described as highly aggres-
sive and a low-TF producer [20]. It was chosen for the pres-
ent studies because WM-115 cells produce CP that may 
potentially play the role in generating bleeding disorders 
in melanoma patients.
In this study we analyze human breast cancer cell line 
MCF-7 and human malignant melanoma cell line WM-115 
in order to characterize the cellular expression of CP and 
evaluate whether ATO may affect this activity, as well as 
the viability of the cells after arsenic trioxide treatment.
Material and methods
Arsenic trioxide
Arsenic trioxide (Sigma, USA) was dissolved in phosphate 
buffered saline (PBS) (Gibco, UK) at a concentration of 1mM 
as a stock solution and diluted to a working solution before 
use. In accordance with the range of ATO peak serum con-
centrations in blood of patients with APL, similar concentra-
tions of ATO (0.1, 0.5, 1, 1.5, 2, 5 and 10 μM) were tested.
Cell culture
Human breast cancer cell line MCF-7 and human ma-
lignant melanoma cell line WM-115 were cultured at 37˚C 
in a 5% CO
2
/95% air atmosphere. MCF-7 cell line is estro-
gen-receptor positive (ER+) and it is characterized as low 
metastatic in vivo [21]. WM-115 cell line is described as 
highly aggressive and metastatic, and a low TF-produc-
er [20]. Culture media consisted of Dulbecco’s Modified 
Eagle Medium (DMEM) (Gibco, UK), supplemented with 
gentamycin (20 μg/ml) (Polfa, Poland) and 10% fetal calf 
serum (Gibco, UK) inactivated at 56˚C for 30 min. The cells 
were cultured in 75 cm2 flask (Nunc, Denmark) and con-
fluent monolayer was trypsynized using 0.25% trypsin 
(Biomed, Poland) containing 5.3 mM EDTA (POCH, Poland). 
Cell viability was evaluated with trypan blue exclusion dye 
(Sigma, USA) and was always above 98%.
Cancer procoagulant activity assay
For CP activity assays, cells were placed into 24-well 
plates (Nunc, Denmark) (MCF-7: 1000 μl of cell suspension 
containing 20000 cells/well; WM-115: 1000 μl cell suspen-
sion containing 10000 cells/well) and cultured for 24 h 
(WM-115) or 48 h (MCF-7) to allow for cell attachment. Then 
the cells were treated with serum free medium in absence 
(control cells were treated with the vehicle of As
2
O
3
) or pres-
ence of As
2
O
3
 (0.1, 0.5, 1, 1.5, 2, 5 and 10 μM). After incuba-
tion for 24, 48, 72, 96, 120 hours monolayer of MCF-7 cell in 
the 24-well plate (Nunc, Denmark) was briefly washed with 
PBS buffer (Gibco, UK) then 20 mM Tris (Sigma, USA) buffer 
pH 7.8 was added (1 ml/well) and the plate was placed at 
+4˚C for overnight to obtain the cells extracts.
CP activity was determined in the cell lysates by a spe-
cific three-stage chromogenic assay modified to micro-
plate format [22]. Briefly, 50 μl of TRIS cell extract was 
mixed with 5 μl of human factor X (100 μg/ml) and 15 μl 
of 25 mM CaCl
2
 (Sigma, USA) in 50mM bis-Tris propane 
(Sigma, USA) buffer (pH 6.7). After 30 minutes of incuba-
tion at 37°C, 5 μl of human prothrombin (1 mg/ml) and 
15 μl of rabbit brain cephalin (RBC)/Ca2+ mix were add-
ed to the samples [(RBC)/Ca2+ mix = 1 part of a RBC 10× 
diluted with water + 1 part of 50 mM CaCl
2 
+ 2 parts of 
100 mM bis-Tris propane buffer (pH 7.8)]. After further 30 
minutes of incubation at 37°C, the thrombin substrate Sar-
Pro-Arg-p-nitroanilide (2 mM in 10% DMSO) (Sigma, USA) 
was added. Color development at 405 nm was recorded in 
time. Samples CP content was expressed as mU/ml (1 U = 
the amount of enzyme responsible for releasing 1 μmol of 
p-nitroanilide from the substrate in 1 minute).
MTT cell proliferation test 
The test was performed to assess cell viability after 
treatment with increasing concentrations of arsenic tri-
oxide. The MTT test is based on reduction of tetrazolium 
salt by mitochondrial enzymes, which is possible only in 
live cells. Therefore, 3-[4,5-dimethylthiazol-2-yl]-2,5 diphen-
yltetrazolium bromide (MTT) (Sigma, USA) was dissolved in 
sterile phosphate-buffered saline (Gibco, UK) (PBS solution 
5mg/ml) and added to cell cultures according to the meth-
od already described [23]. For proliferation assays, cells 
were placed into 96-well plates (Nunc, Denmark) (MCF-7: 
100 μl of cell suspension containing 5000 cells/well; 
WM-115: 100 μl cell suspension containing 1000 cells/well) 
and cultured for 24 h (WM-115) or 48 h (MCF-7) to allow for 
cell attachment. Then cells were treated with serum free 
medium in absence (control cells were treated with the 
vehicle of As
2
O
3
) or presence of As
2
O
3
 (0.1, 0.5, 1, 1.5, 2, 5 and 
10 μM). After 24, 48, 72, 96, 120 hours of incubation, 10 μl 
of MTT was added to each well and incubated for another 
2 hours. Then 100 μl of stop mix solution [20% SDS (Sigma, 
USA) in 50% dimethyl formamide (Sigma, USA)] was added 
to each well and incubated overnight to dissolve the dark-
blue formazan crystals formed. Finally, the absorbance 
was measured with a spectrophotometer at 570 nm. All 
the tests were carried out in triplicate and compared with 
control wells in which no arsenic trioxide was added. Cell 
survival rate was calculated with the following equation: 
average absorbance value of experimental group/average 
absorbance value of control group × 100%.
Results
Cancer procoagulant activity 
The cells were exposed to 0.1, 0.5, 1, 1.5, 2, 5 or 10 μM 
ATO for 24, 48, 72, 96 or 120 h. For both cell lines CP activ-
ity was expressed as the percentage of CP control activity 
(Fig. 1). Cancer procoagulant activity in MCF-7 control cells 
group was between 2600–6800 mU/mg and in WM-115 
control cells group between 1600–6900 mU/mg (Table 1).
MCF-7 cell line
The time- and dose-dependent effect of ATO on CP ac-
tivity was observed over the ATO concentration and over 
the entire incubation period. After 24 h of incubation with 
5 μM and 10 μM ATO CP activity was reduced to 64% and 
58% of control respectively and the activity was barely 
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detectable after 120 h of incubation. For lower concentra-
tions of ATO a significant decrease in CP activity was also 
observed and it was 60% after 120 h of incubation for 0.5 
μM concentration of ATO. 
WM-115 cell line
The CP activity was decreased to 89% after 24 h incu-
bation with the lowest 0.1 μM arsenic trioxide dose. Higher 
doses: 0.5–10 μM caused inhibition in CP activity below 80% 
within 48 h incubation compared with untreated control. 
This reduction was followed by increase after 48 hours. How-
ever, the loss of CP activity after 120 h incubation for 10 μM 
concentration of arsenic was also observed. All data were 
considered statistically significant (p values were < 0.01).
Cell proliferation 
MTT assay results were expressed as the percentage of 
the control cell viability (Fig. 2). 
MCF-7 cell line
The MTT test demonstrated that ATO did not affect 
cell proliferation. For most time periods and ATO concen-
trations the cell viability was performed around 100% of 
control. The inhibition of the cell proliferation to 74% was 
observed only after 120 h incubation with 10 μM ATO.
WM-115 cell line
The response showed no change in cell viability with-
in dose range between 0.1–1.5 μM, followed by a gradual 
decline. Application of 5 μM and 10 μM ATO resulted in re-
duction to 37% and 0% of cell viability respectively within 
120 h incubation compared with control. 
Discussion
The aim of present work was to evaluate the arsenic 
trioxide influence on the CP activity in MCF-7 and WM-115 
cell line in vitro. In this study we demonstrate for the first 
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Fig. 1. Cancer procoagulant activity in cultured MCF-7 and WM–115 cells after exposition to arsenic trioxide
Data are expressed as a percentage of cancer procoagulant (CP) activity with respect to untreated control. The results are expressed as the mean of three different 
experiments, ± SD. * the differences were statistically significant, the p values were < 0.01
MCF-7
MCF-7
WM–115
WM-115
Table 1. Cancer procoagulant activity (mU/mg) 
MCF-7 WM-115
24 h 2697 ±899 2920 ±343
48 h 3891 ±387 1587 ±293
72 h 6887 ±926 3150 ±894
96 h 5539 ±700 3040 ±559
120 h 6783 ±879 6990 ±990
Cancer procoagulant activity in cultured MCF-7 and WM-115 control cells (untre-
ated cells). The results are expressed as the mean of at least three different expe-
riments, ± SD.
Fig. 2. Cytostatic effect of arsenic trioxide on cultured MCF–7 and WM–115 cells
Data are expressed as the percent of live cells relative to uncreated control. The results are expressed as the mean of three different experiments, ± SD. * results were 
considered statistically significant, the p values were < 0.01
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time that ATO can reduce CP activity of breast and mela-
noma cancer cells. The effect is getting stronger together 
with the increase of ATO dose. 
Cancer procoagulant directly activates blood coagu-
lation factor X in absence of activated factor VII. Cancer 
procoagulant is described in malignant and fetal tissues, 
but its genomic sequence is unknown [10, 24]. Cancer pro-
coagulant activity reduction as a result of the application 
of different cytostatics e.g. all-trans retinoic acid (ATRA), 
was previously described [10, 13, 25]. Marchetti et al. [10] 
demonstrated that ATRA downregulates the expression of 
TF and CP in breast cancer cells. In our study it was shown 
for the first time that also arsenic trioxide induces reduc-
tion in CP activity. The mechanism of ATO action is still un-
clear, but obviously it is different in breast and melanoma 
cancer cells. It is probably associated with different charac-
terization of these two cancer types. Firstly, MCF-7 cells are 
non-aggressive while WM-115 cells are described as highly 
malignant. Secondly, MCF-7 cells are estrogen-dependent 
in contrast to WM-115, which do not depend on hormones 
for growth [21]. MCF-7 cells express estrogen and proges-
terone receptors [26]. Finally, there is a difference in TF and 
CP expression. MCF-7 cells express both proteins while 
WM-115 cells are known as a very low TF-producer [20]. The 
WM-115 lysates contain no TF and enzymatic characteris-
tics of the procoagulant activity was typical for CP [24]. 
Similarity in therapeutic effect of ATO and ATRA in leu-
kemic cells suggests a similarity in their mechanism of 
action. According to Marchetti et al. [10], ATRA affected 
CP expression in estrogen receptor positive and nega-
tive breast cell lines. Falanga et al. [27] presented that 
ATRA-induced modulation of CP occurs in parallel with 
signs of cell differentiation [27]. Moreover, it has been ev-
idenced that CP activity loss is correlated with remission 
of cancer [28, 29]. We observed reduction in CP expres-
sion in MCF-7 cells in dose and time-dependent manner, 
but ATO did not inhibit cell proliferation. The cells grew 
with similar velocity to a control group. Any variation in 
cell proliferation had not been found statistically signifi-
cant. It seems that MCF-7 cells are resistant to apoptotic 
effect of ATO. It may be due to lack of caspase-3 expres-
sion which is crucial for apoptosis induction [30–32]. On 
the other hand, in APL cells, the downregulation of CP 
by ATRA is associated with cell differentiation and can-
cer remission [27]. More studies need to be performed 
to check cell morphology after arsenic trioxide treatment 
and verify if cells proliferation is correlated with cell dif-
ferentiation to normal cells. 
The results obtained from melanoma cells investigation 
indicated on decreasing CP activity followed by a gradu-
al increase. The loss of CP activity was observed after 24 h 
incubation with the whole range of ATO concentration. The 
higher concentration of ATO, the higher reduction in CP ac-
tivity compared to control. The loss in CP activity was main-
tained within next two days of incubation. However, longer 
incubation time resulted in new rising of CP activity. It seems 
that melanoma cells are sensitive to ATO at the beginning 
of treatment. Probably, some of the cells meet apoptosis 
and those, which are still vivid, became resistant in longer 
course. The results from MTT showed that antiproliferative 
effect of ATO on WM-115 is dose- and time-correlated within 
2–5 μM concentration range. It was also observed slightly 
increase in cell viability below 2 μM concentration, however 
there is no statistically significant difference. These results 
are in agreement with previous studies separately performed 
in diverse cell types, which have contributed to explain the 
carcinogenic properties of arsenic [33–35]. The increasing CP 
activity was possibly due to feedback regulation of CP. More 
researches should be done to verify this thesis. 
All in all, we demonstrate arsenic impact on CP activi-
ty in breast and melanoma cancer cells. Since coagulation 
activation plays a pivotal role in tumor progression, further 
studies should check if the capacity of ATO to decrease CP 
correlate with total procoagulant activity. Obtained results 
may open new perspectives in tumor therapy. 
In conclusion, this study demonstrates for the first 
time that arsenic trioxide downegulates the CP activity in 
breast and melanoma cancer cells and could reduce the vi-
ability of melanoma cells. Results of present work may be 
significant for understanding the nature of some cancer 
associated hypercoagulation. 
The authors declare no conflict of interest.
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